Skip to content

EASE TRICUSPID Expertise-based Assessment Study on Clinical Efficacy of Contour 3D® in TRICUSPID Valve Annuloplasty

EASE TRICUSPID Expertise-based Assessment Study on Clinical Efficacy of Contour 3D® in TRICUSPID Valve Annuloplasty

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01532921
Enrollment
85
Registered
2012-02-15
Start date
2011-01-31
Completion date
2016-01-31
Last updated
2018-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tricuspid Valve Insufficiency

Brief summary

Few clinical evidence for the Contour 3D Tricuspid Annuloplasty Ring exists; therefore, in order to position this product on the market, a post-market release study was completed. The purpose of this study was to evaluate the hemodynamic performance of the Contour 3D® Tricuspid Annuloplasty Ring following Tricuspid Valve (TV) repair in a post-market environment.

Detailed description

The EASE TRICUSPID Clinical Trial was a prospective, non-randomized, non-interventional, post-market release study. The purpose of this study was to evaluate the hemodynamic performance of the Contour 3D® Tricuspid Annuloplasty Ring following Tricuspid Valve (TV) repair in a post-market environment. Therefore, the primary objective of the EASE Tricuspid Study was to evaluate the hemodynamic performance of the Contour 3D® Tricuspid Annuloplasty Ring (Contour 3D ring) in subjects with tricuspid regurgitation who had a clinical indication for TV repair in a post-market use. Secondary objectives included the evaluation of the effect of TV repair with the Contour 3D ring on the right ventricular function, as well as the assessment of the effect of TV repair with the Contour 3D ring on the functional status in subjects undergoing TV repair in a post-market environment. Subjects eligible for TV repair and compliant with the enrollment criteria were considered by the Investigator for inclusion in the study. To minimize bias, enrolled subjects were followed by their own physician in accordance with the center's established practice for routine follow up. Follow-up sessions were planned at the physician's discretion. To meet the intended goals, appropriate clinical data were collected at baseline (pre-surgery), during the surgical procedure, at discharge and during the follow-up period at 6 months. Experienced echo-cardiologists evaluated the echos. At the time of enrollment it was not certain if the subject would receive a Contour 3D ring, since the surgeon might have decided during surgery that another treatment was more beneficial to the subject. In this case, the subject was terminated from the study.

Interventions

PROCEDURELeft-sided heart surgery

Tricuspid valve repair was with the study device was only warranted if concomitant left-sided heart surgery was planned

DEVICEContour 3D Tricuspid Annuloplasty Ring

Contour 3D Tricuspid Annuloplasty procedure was used during the tricuspid valve repair

Sponsors

Medtronic Cardiac Rhythm and Heart Failure
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Willing to sign and date the Patient Informed Consent (PIC) * Indicated for a concomitant surgical repair of the TV * Willing to return to the hospital, where the implantation originally occurred, for a 6 month follow-up visit

Exclusion criteria

* Patients with a degenerative TV condition * Patients with primary TV regurgitation * Previous TV repair or replacement * Stand-alone TV repair * Already participating in another investigational device or drug study, possibly leading to bias and jeopardizing the scientific appropriate assessment of the study endpoints * Life expectancy of less than one year * Pregnant or desire to be pregnant within 12 months of the study treatment * Under 18 years or over 85 years of age * Patients with active endocarditis * Patients with valvular retraction with severely reduced mobility * Patients with a heavily calcified TV

Design outcomes

Primary

MeasureTime frameDescription
Change in the Degree of Tricuspid Valve (TV) Leaflet Tethering Height From Baseline Through 6 Months Post-implantBaseline to Discharge (up to 5 days post-implant) and 6 months post-implantChange in the degree of TV leaflet tethering height measured via echocardiography from Baseline through 6 months post-implant
Mean Gradient Across the Tricuspid ValveAt Baseline, Discharge (up to 5 days post-implant) and 6 months post-implantThe mean gradient across the Tricuspid Valve (TV) measured via echocardiography at discharge (up to 5 days post-implant) through 6 months post-implant
Change in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implantBaseline to Discharge (up to 5 days post-implant) and through 6 months post-implantChange in the degree of tricuspid regurgitation measured via echocardiography from Baseline through 6 months post-implant. The severity of tricuspid regurgitation is graded by using several qualitative and quantitative methods. The degree of regurgitation is classified as none, Mild, Moderate or Severe.
Change in Tricuspid Valve (TV) Leaflet Coaptation Length From Baseline Through 6 Months Post-implantBaseline to Discharge (up to 5 days post-implant) and to 6 months post-implantChange in the degree of TV leaflet coaptation length measured via echocardiography from Baseline through 6 months post-implant

Secondary

MeasureTime frameDescription
Change in the Right Ventricle (RV) Diastolic Area From Baseline Through 6 Months Post-implantBasline to Discharge (up to 5 days post-implant) and 6 months post-implant
Change in the Tricuspid Annular Diameter Measured at Diastole From Baseline Through 6 Months Post-implantBaseline to Discharge (up to 5 days post-implant) and 6 months post-implant
Change in the Right Ventricle (RV) Fractional Area From Baseline Through 6 Months Post-implantBaseline to Discharge (up to 5 days post-implant) and 6 months post-implant
Change in New York Heart Association (NYHA) Classification From Baseline Through 6 Months Post-implantBaseline to Discharge (up to 5 days post-implant) and 6 months post-implantThe New York Heart Association (NYHA) Functional Classification provides a simple way of classifying the extent of heart failure. It places patients in one of four categories based on how much they are limited during physical activity; the limitations/symptoms are in regard to normal breathing and varying degrees in shortness of breath and/or angina. NYHA I implies no limitations. NYHA II implies slight limitation of physical activity. NYHA III implies marked limitation of physical activity and finally, NYHA IV implies patients are Unable to carry on any physical activity without discomfort.

Countries

France, Germany, Israel

Participant flow

Participants by arm

ArmCount
Indicated for a TV Repair Procedure
All patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for whom the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.
76
Total76

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyDeath3
Overall StudyDevice was explanted during procedure1
Overall StudyLost to Follow-up3
Overall StudyPhysician Decision7
Overall StudyWithdrawal by Subject2

Baseline characteristics

CharacteristicIndicated for a TV Repair Procedure
Age, Continuous72.2 years
STANDARD_DEVIATION 7.2
EuroSCORE II percentage score8.7 percentage
STANDARD_DEVIATION 9.4
NYHA Class
NYHA Class I
4 Participants
NYHA Class
NYHA Class II
23 Participants
NYHA Class
NYHA Class III
40 Participants
NYHA Class
NYHA Class IV
9 Participants
Sex: Female, Male
Female
36 Participants
Sex: Female, Male
Male
40 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
3 / 76
other
Total, other adverse events
46 / 76
serious
Total, serious adverse events
45 / 76

Outcome results

Primary

Change in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implant

Change in the degree of tricuspid regurgitation measured via echocardiography from Baseline through 6 months post-implant. The severity of tricuspid regurgitation is graded by using several qualitative and quantitative methods. The degree of regurgitation is classified as none, Mild, Moderate or Severe.

Time frame: Baseline to Discharge (up to 5 days post-implant) and through 6 months post-implant

Population: Implanted cohort

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
BaselineChange in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implantImproved 4 grades7 Participants
BaselineChange in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implantImproved 2 grades27 Participants
BaselineChange in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implantWorsened 2 grades0 Participants
BaselineChange in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implantImproved 3 grades8 Participants
BaselineChange in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implantWorsened 3 grades0 Participants
BaselineChange in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implantImproved 1 grade21 Participants
BaselineChange in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implantWorsened 4 grades0 Participants
BaselineChange in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implantNo change3 Participants
Discharge (up to 5 Days Post-implant)Change in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implantWorsened 4 grades0 Participants
Discharge (up to 5 Days Post-implant)Change in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implantImproved 4 grades7 Participants
Discharge (up to 5 Days Post-implant)Change in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implantImproved 3 grades10 Participants
Discharge (up to 5 Days Post-implant)Change in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implantImproved 2 grades31 Participants
Discharge (up to 5 Days Post-implant)Change in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implantImproved 1 grade16 Participants
Discharge (up to 5 Days Post-implant)Change in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implantNo change1 Participants
Discharge (up to 5 Days Post-implant)Change in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implantWorsened 2 grades0 Participants
Discharge (up to 5 Days Post-implant)Change in the Degree of Tricuspid Regurgitation From Baseline Through Discharge (up to 5 Days Post-implant) and 6 Months Post-implantWorsened 3 grades0 Participants
Primary

Change in the Degree of Tricuspid Valve (TV) Leaflet Tethering Height From Baseline Through 6 Months Post-implant

Change in the degree of TV leaflet tethering height measured via echocardiography from Baseline through 6 months post-implant

Time frame: Baseline to Discharge (up to 5 days post-implant) and 6 months post-implant

Population: Implanted cohort

ArmMeasureValue (MEAN)Dispersion
BaselineChange in the Degree of Tricuspid Valve (TV) Leaflet Tethering Height From Baseline Through 6 Months Post-implant-0.2 mmStandard Deviation 5.3
Discharge (up to 5 Days Post-implant)Change in the Degree of Tricuspid Valve (TV) Leaflet Tethering Height From Baseline Through 6 Months Post-implant-0.5 mmStandard Deviation 5.2
Primary

Change in Tricuspid Valve (TV) Leaflet Coaptation Length From Baseline Through 6 Months Post-implant

Change in the degree of TV leaflet coaptation length measured via echocardiography from Baseline through 6 months post-implant

Time frame: Baseline to Discharge (up to 5 days post-implant) and to 6 months post-implant

Population: Implanted cohort

ArmMeasureValue (MEAN)Dispersion
BaselineChange in Tricuspid Valve (TV) Leaflet Coaptation Length From Baseline Through 6 Months Post-implant-0.6 mmStandard Deviation 4.6
Discharge (up to 5 Days Post-implant)Change in Tricuspid Valve (TV) Leaflet Coaptation Length From Baseline Through 6 Months Post-implant0.0 mmStandard Deviation 5.1
Primary

Mean Gradient Across the Tricuspid Valve

The mean gradient across the Tricuspid Valve (TV) measured via echocardiography at discharge (up to 5 days post-implant) through 6 months post-implant

Time frame: At Baseline, Discharge (up to 5 days post-implant) and 6 months post-implant

Population: Implanted cohort

ArmMeasureValue (MEAN)Dispersion
BaselineMean Gradient Across the Tricuspid Valve1.3 mmHgStandard Deviation 0.6
Discharge (up to 5 Days Post-implant)Mean Gradient Across the Tricuspid Valve2.0 mmHgStandard Deviation 1
6 Months Follow-UpMean Gradient Across the Tricuspid Valve1.9 mmHgStandard Deviation 0.9
Secondary

Change in New York Heart Association (NYHA) Classification From Baseline Through 6 Months Post-implant

The New York Heart Association (NYHA) Functional Classification provides a simple way of classifying the extent of heart failure. It places patients in one of four categories based on how much they are limited during physical activity; the limitations/symptoms are in regard to normal breathing and varying degrees in shortness of breath and/or angina. NYHA I implies no limitations. NYHA II implies slight limitation of physical activity. NYHA III implies marked limitation of physical activity and finally, NYHA IV implies patients are Unable to carry on any physical activity without discomfort.

Time frame: Baseline to Discharge (up to 5 days post-implant) and 6 months post-implant

Population: Implanted cohort

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
BaselineChange in New York Heart Association (NYHA) Classification From Baseline Through 6 Months Post-implantWorsened 2 classes0 Participants
BaselineChange in New York Heart Association (NYHA) Classification From Baseline Through 6 Months Post-implantWorsened 3 classes0 Participants
BaselineChange in New York Heart Association (NYHA) Classification From Baseline Through 6 Months Post-implantImproved 3 classes0 Participants
BaselineChange in New York Heart Association (NYHA) Classification From Baseline Through 6 Months Post-implantImproved 2 classes2 Participants
BaselineChange in New York Heart Association (NYHA) Classification From Baseline Through 6 Months Post-implantImproved 1 class6 Participants
BaselineChange in New York Heart Association (NYHA) Classification From Baseline Through 6 Months Post-implantNo change4 Participants
BaselineChange in New York Heart Association (NYHA) Classification From Baseline Through 6 Months Post-implantWorsened 1 class1 Participants
Discharge (up to 5 Days Post-implant)Change in New York Heart Association (NYHA) Classification From Baseline Through 6 Months Post-implantImproved 1 class28 Participants
Discharge (up to 5 Days Post-implant)Change in New York Heart Association (NYHA) Classification From Baseline Through 6 Months Post-implantWorsened 1 class3 Participants
Discharge (up to 5 Days Post-implant)Change in New York Heart Association (NYHA) Classification From Baseline Through 6 Months Post-implantWorsened 2 classes0 Participants
Discharge (up to 5 Days Post-implant)Change in New York Heart Association (NYHA) Classification From Baseline Through 6 Months Post-implantImproved 2 classes15 Participants
Discharge (up to 5 Days Post-implant)Change in New York Heart Association (NYHA) Classification From Baseline Through 6 Months Post-implantWorsened 3 classes0 Participants
Discharge (up to 5 Days Post-implant)Change in New York Heart Association (NYHA) Classification From Baseline Through 6 Months Post-implantNo change13 Participants
Discharge (up to 5 Days Post-implant)Change in New York Heart Association (NYHA) Classification From Baseline Through 6 Months Post-implantImproved 3 classes3 Participants
Secondary

Change in the Right Ventricle (RV) Diastolic Area From Baseline Through 6 Months Post-implant

Time frame: Basline to Discharge (up to 5 days post-implant) and 6 months post-implant

Population: Implanted Cohort

ArmMeasureValue (MEAN)Dispersion
BaselineChange in the Right Ventricle (RV) Diastolic Area From Baseline Through 6 Months Post-implant160.5 mm2Standard Deviation 481.3
Discharge (up to 5 Days Post-implant)Change in the Right Ventricle (RV) Diastolic Area From Baseline Through 6 Months Post-implant50.0 mm2Standard Deviation 406.4
Secondary

Change in the Right Ventricle (RV) Fractional Area From Baseline Through 6 Months Post-implant

Time frame: Baseline to Discharge (up to 5 days post-implant) and 6 months post-implant

Population: Implanted cohort

ArmMeasureValue (MEAN)Dispersion
BaselineChange in the Right Ventricle (RV) Fractional Area From Baseline Through 6 Months Post-implant1.7 percentage of changeStandard Deviation 13.4
Discharge (up to 5 Days Post-implant)Change in the Right Ventricle (RV) Fractional Area From Baseline Through 6 Months Post-implant-1.0 percentage of changeStandard Deviation 17
Secondary

Change in the Tricuspid Annular Diameter Measured at Diastole From Baseline Through 6 Months Post-implant

Time frame: Baseline to Discharge (up to 5 days post-implant) and 6 months post-implant

Population: Data were not collected

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026